Optipharm.CO.LTD Past Earnings Performance
Past criteria checks 0/6
Optipharm.CO.LTD's earnings have been declining at an average annual rate of -9%, while the Biotechs industry saw earnings growing at 2.7% annually. Revenues have been growing at an average rate of 7.8% per year.
Key information
-9.0%
Earnings growth rate
-8.5%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 7.8% |
| Return on equity | -9.7% |
| Net Margin | -11.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Health Check: How Prudently Does Optipharm.CO.LTD (KOSDAQ:153710) Use Debt?
Mar 30
What Kind Of Shareholders Hold The Majority In Optipharm.CO.,LTD's (KOSDAQ:153710) Shares?
Feb 23Should Optipharm.CO.LTD (KOSDAQ:153710) Be Disappointed With Their 52% Profit?
Jan 19
Optipharm.CO.LTD (KOSDAQ:153710) Has Debt But No Earnings; Should You Worry?
Dec 15Revenue & Expenses Breakdown
How Optipharm.CO.LTD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 19,085 | -2,269 | 3,601 | 2,845 |
| 30 Jun 24 | 18,560 | -2,453 | 3,499 | 2,877 |
| 31 Mar 24 | 17,775 | -2,353 | 3,295 | 2,967 |
| 31 Dec 23 | 17,373 | -2,437 | 3,300 | 2,946 |
| 30 Sep 23 | 16,835 | -2,144 | 3,113 | 2,049 |
| 30 Jun 23 | 16,568 | -2,078 | 2,836 | 2,374 |
| 31 Mar 23 | 16,408 | -2,045 | 2,700 | 2,500 |
| 31 Dec 22 | 16,008 | -2,045 | 2,546 | 2,632 |
| 30 Sep 22 | 15,703 | -2,163 | 2,534 | 3,693 |
| 30 Jun 22 | 15,054 | -2,399 | 2,550 | 3,859 |
| 31 Mar 22 | 14,307 | -2,800 | 2,614 | 4,235 |
| 31 Dec 21 | 14,258 | -3,080 | 2,730 | 5,022 |
| 30 Sep 21 | 13,493 | -3,761 | 2,915 | 5,291 |
| 30 Jun 21 | 13,546 | -3,520 | 2,964 | 5,178 |
| 31 Mar 21 | 13,282 | -3,189 | 3,006 | 4,664 |
| 31 Dec 20 | 13,046 | -2,352 | 2,818 | 3,670 |
| 30 Sep 20 | 12,988 | -2,013 | 2,862 | 2,977 |
| 30 Jun 20 | 12,981 | -1,549 | 2,710 | 2,517 |
| 31 Mar 20 | 13,412 | -839 | 2,786 | 2,289 |
| 31 Dec 19 | 13,653 | -655 | 2,975 | 2,168 |
| 30 Sep 19 | 14,017 | -525 | 3,355 | 2,147 |
| 30 Jun 19 | 13,959 | -697 | 3,718 | 2,096 |
| 31 Mar 19 | 14,026 | -829 | 3,747 | 2,096 |
| 31 Dec 18 | 13,958 | -604 | 3,795 | 1,985 |
| 30 Jun 18 | 13,732 | -992 | 3,707 | 1,826 |
| 31 Dec 17 | 13,857 | -1,567 | 3,772 | 1,710 |
| 31 Dec 16 | 14,376 | -348 | 2,722 | 1,286 |
| 31 Dec 15 | 11,425 | -2,209 | 3,525 | 318 |
| 31 Dec 14 | 11,564 | -2,026 | 3,753 | 696 |
| 31 Dec 13 | 7,592 | -1,225 | 3,103 | 914 |
Quality Earnings: A153710 is currently unprofitable.
Growing Profit Margin: A153710 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A153710 is unprofitable, and losses have increased over the past 5 years at a rate of 9% per year.
Accelerating Growth: Unable to compare A153710's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A153710 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.8%).
Return on Equity
High ROE: A153710 has a negative Return on Equity (-9.68%), as it is currently unprofitable.